NOTCH3 and prostate cancer: In colorectal cancer (DFS GSE = 17,536(177 sample)23, HR = 0.93, P = 0.000083; DFS GSE = 14,333(290 sample)24, HR = 0.64, P = 0.000099) and prostate cancer (OS GSE = 16,560(186 sample)25, HR = 0.34, P = 0.000110) (Fig. 3C), there was a marginally negative correlation found between high expression of NOTCH3 and a poor prognosis.Low NOTCH3 expression was marginally associated with a worse prognosis in one cohort (GSE12093, HR = 1.29, P = 0.000505) (136 samples)26, which included 136 samples at the DMFS stage of breast cancer.